Clinical Trial

Crizanlizumab Pregnancy Outcomes Intensive Monitoring

Name: Crizanlizumab Pregnancy Outcomes Intensive Monitoring — clinical trial record (NCT07554547)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PRIM

Completed

View on ClinicalTrials.gov →

Summary

This was a non-interventional study to evaluate pre-specified pregnancy and infant outcomes in women treated with crizanlizumab during pregnancy or within 105 days before the last menstrual period (LMP).

Trial Details

NCT Number	NCT07554547
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Sickle Cell Disease
Enrollment	13 participants
Start Date	2020-11-15
Primary Completion	2025-06-30 (estimated)
Study Completion	2025-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-28